drugset / Trial / NCT01898338

Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia

NCT01898338

RandomizedParallel-groupOpen-labelTreatment

Summary

To demonstrate that the combination of daptomycin and fosfomycin is superior to daptomycin alone in the treatment of methicillin resistant Staphylococcus aureus (MRSA) bacteremia.

Timeline

Start
2013-12
Primary completion
2018-01-10
Completion
2018-01-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 10 mg/kg Intravenous
Subject Fosfomycin Small molecule 2 g Intravenous